National Organization for Drug Control & Research, Cairo, Egypt.
Pharmacognosy Department College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Arch Physiol Biochem. 2020 May;126(2):116-128. doi: 10.1080/13813455.2018.1498902. Epub 2018 Sep 29.
Chronic hepatitis C virus (HCV) infection is a significant public health problem, with a worldwide prevalence of approximately 170 million. Current therapy for HCV infection includes the prolonged administration of a combination of ribavirin and PEGylated interferon-α, for over a decade. This regimen is expensive and often associated with a poor antiviral response and unwanted side effects. A highly effective combination treatment is likely required for the future management of HCV infections and entry inhibitors could play an important role. Currently, no entry inhibitor has been licensed for the prophylactic treatment of hepatitis C. Therefore, additional agents that combat HCV infection are urgently needed and must be developed. Many phytochemical constituents have been identified that display considerable inhibition of HCV at some stage of the life cycle. This review will summarise the current state of knowledge on natural products and their possible activities in the context of HCV infection.
慢性丙型肝炎病毒（HCV）感染是一个重大的公共卫生问题，全球约有 1.7 亿人感染。目前治疗 HCV 感染的方法包括使用利巴韦林和聚乙二醇干扰素-α联合治疗，持续时间超过十年。这种治疗方案费用昂贵，往往与抗病毒反应不佳和不良反应有关。未来 HCV 感染的管理可能需要一种高度有效的联合治疗方法，而进入抑制剂可能会发挥重要作用。目前，尚无进入抑制剂被批准用于丙型肝炎的预防性治疗。因此，迫切需要开发针对 HCV 感染的其他药物。已经鉴定出许多植物化学成分，它们在 HCV 生命周期的某个阶段显示出相当大的抑制作用。本综述将总结目前关于天然产物及其在 HCV 感染方面可能的活性的知识状况。
